Janux Therapeutics (JANX) Other financing activities (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Other financing activities of $3.5 million for Q1 2026, up 293.45% year-over-year from $901000.0 in Q1 2025, and up 293.45% quarter-over-quarter from $901000.0 in Q1 2025.
Janux Therapeutics (JANX) Other financing activities (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Other financing activities for 6 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 293.45% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $7.7 million (up 85.67% YoY), while the FY2021 annual figure was $204.2 million, changed N/A from the prior year.
- Other financing activities rose to $3.5 million in Q1 2026 per JANX's latest filing, from $901000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3.5 million in Q1 2026 and bottomed at $901000.0 in Q1 2025.
- Historically, Other financing activities has averaged $1.9 million across 4 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2025 — Other financing activities slumped 45.62% — and 2026, when it jumped 293.45%.
- Janux Therapeutics' Other financing activities stood at $1.6 million in 2023, then rose by 4.87% to $1.7 million in 2024, then plunged by 45.62% to $901000.0 in 2025, then surged by 293.45% to $3.5 million in 2026.
- Business Quant data shows JANX's Other financing activities at $3.5 million in Q1 2026, $901000.0 in Q1 2025, and $1.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.55 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Mar 31, 2025 | 901,000.00 |
| Mar 31, 2025 | 901,000.00 |
| Mar 31, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Sep 30, 2021 | -843,000.00 |
| Sep 30, 2021 | -843,000.00 |
| Dec 31, 2020 | -4,000.00 |
| Dec 31, 2020 | -4,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Sep 30, 2020 | 4,000.00 |